Lucinactant: In neonatal respiratory distress syndrome

Treatments in Respiratory Medicine

Volumn 4, Issue 2, 2005, Pages 139-145

  Moen, Marit D ^a   Perry, Caroline M ^a   Wellington, Keri ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL LUNG SURFACTANT; BERACTANT; DIPALMITOYLPHOSPHATIDYLCHOLINE; LUCINACTANT; LUNG SURFACTANT; PEPTIDE; PHOSPHOLIPID; PORACTANT; SINAPULTIDE; UNCLASSIFIED DRUG;

ADULT RESPIRATORY DISTRESS SYNDROME; APNEA; ARTICLE; BRADYCARDIA; BRAIN HEMORRHAGE; CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; LUNG DYSPLASIA; LUNG FUNCTION; LUNG HEMORRHAGE; MECONIUM ASPIRATION; MORTALITY; NECROTIZING ENTEROCOLITIS; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; NONHUMAN; PALLOR; PREMATURITY; PRIORITY JOURNAL; SEPSIS; SURFACE TENSION; SURVIVAL RATE;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; ANIMALS; ANIMALS, NEWBORN; BIOLOGICAL PRODUCTS; DRUG COMBINATIONS; FATTY ALCOHOLS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; PEPTIDES; PHOSPHOLIPIDS; PHOSPHORYLCHOLINE; POLYETHYLENE GLYCOLS; PULMONARY SURFACTANTS; RESPIRATORY DISTRESS SYNDROME, ADULT; SURFACE TENSION; TREATMENT OUTCOME;

EID: 18144367376     PISSN: 11763450     EISSN: None     Source Type: Journal    
DOI: 10.2165/00151829-200504020-00008     Document Type: Article

References (24)

1. Boyd S. Causes and treatment of neonatal respiratory distress syndrome. Nurs Times 2004 Jul; 100 (30): 40-4
2. Lewis JF. Surfactant: where are we in 2003? Can Respir J 2004; 11 (3): 204-6
3. Suresh GK, Soll RF. Lung surfactants for neonatal respiratory distress syndrome: animal-derived or synthetic agents? Pediatric Drugs 2002; 4 (No. 8): 485-92
4. Ainsworth SB, Milligan DWA. Surfactant therapy for respiratory distress syndrome in premature neonates: A comparative review. Am J Respir Med 2002; 1 (6): 417-33
5. Data on file. Discovery Laboratories, 2005
6. Cochrane CG, Revak SD. Pulmonary surfactant protein B (SP-B): structure-function relationships. Science 1991 Oct 25; 254 (5031): 566-8
7. Notter RH, Wang Z, Egan EA, et al. Component-specific surface and physiological activity in bovine-derived lung surfactants. Chem Phys Lipids 2002 Jan; 114 (1): 21-34
8. Physicians' Desk Reference. Montvale (NJ): Thomson PDR, 2005
9. Doyle I. Lucinactant (Discovery Laboratories). Idrugs 2002 Jul; 5 (7): 696-702
10. Cruz A, Vazquez L, Velez M, et al. Effect of pulmonary surfactant protein SP-B on the micro- and nanostructure of phospholipid films. Biophys J 2004 Jan; 86 (1): 308-20
11. Cochrane CG, Revak SD. Protein-phospholipid interactions in pulmonary surfactant. Chest 1994 Mar; 105 Suppl. 3: 57S-62S
12. 4) is a transmembrane (α-helix with a mixed nonpolar/polar surface. FEBS Lett 1996 Apr 15; 384 (2): 185-8
13. Ma J, Koppenol S, Yu H, et al. Effects of a cationic and hydrophobic peptide, KL4, on model lung surfactant lipid monolayers. Biophys J 1998 Apr; 74 (4): 1899-907
14. Revak SD, Merritt TA, Cochrane CG, et al. Efficacy of synthetic peptide-containing surfactant in the treatment of respiratory distress syndrome in preterm infant rhesus monkeys. Pediatr Res 1996 Apr; 39 (4 Pt 1): 715-24
15. Nutt M, Patel N, Rairkar M, et al. Comparison of the novel lung surfactant surfaxin® (lucinactant) with currently available commercial products [abstract no. 2912]. Pediatric Academic Societies' Annual Meeting; 2004 May 1-4; San Francisco
16. Merritt TA, Amirkhanian JD, Helbock H, et al. Reduction of the surface-tension-lowering ability of surfactant after exposure to hypochlorous acid. Biochem J 1993 Oct 1; 295: 19-22
17. 4. Pediatr Res 1996 Jun; 39 (6): 947-52
18. Sood SL, Balaraman V, Finn KC, et al. Exogenous surfactants in a piglet model of acute respiratory distress syndrome. Am J Respir Crit Care Med 1996 Feb; 153: 820-8
19. 4 surfactant instillation enhances intrapulmonary distribution in a simian model of respiratory distress syndrome. Pediatr Res 1995 Aug; 38 (2): 211-7
20. Moya F, Gadzinowski J, Bancalari E, et al. A multicenter randomized masked comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome in very preterm infants. Pediatrics (In press)
21. Sinha S, Lacaze-Masmonteil T, Valls i Soler A, et al. A randomized, controlled trial of lucinactant versus poractant alfa in very premature infants at high risk for respiratory distress sydrome. Pediatrics (In press)
22. Discovery Laboratories [online]. Available from URL: http://www.discoverylabs.com
23. 4-surfactant in preterm infants with respiratory distress syndrome. Am J Respir Crit Care Med 1996 Jan; 153: 404-10
24. Suresh GK, Soll RF. Current surfactant use in premature infants. Clin Perinatol 2001 Sep; 28 (3): 671-94